105 related articles for article (PubMed ID: 33144643)
1. Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases.
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Aulicino M; Vaira M; De Franciscis S; D'Acapito F; Carboni F; Milone E; Donini A; Fugazzola P; Faviana P; Sorrentino L; Pizzolato E; Cenzi C; Del Bianco P; Sommariva A
ESMO Open; 2024 Apr; 9(4):102976. PubMed ID: 38613907
[TBL] [Abstract][Full Text] [Related]
2. Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases.
Bootsma S; Dings MPG; Kesselaar J; Helderman RFCPA; van Megesen K; Constantinides A; Moreno LF; Stelloo E; Scutigliani EM; Bokan B; Torang A; van Hooff SR; Zwijnenburg DA; Wouters VM; van de Vlasakker VCJ; Galanos LJK; Nijman LE; Logiantara A; Veenstra VL; Schlingemann S; van Piggelen S; van der Wel N; Krawczyk PM; Platteeuw JJ; Tuynman JB; de Hingh IH; Klomp JPG; Oubrie A; Snaebjornsson P; Medema JP; Oei AL; Kranenburg O; Elbers CC; Lenos KJ; Vermeulen L; Bijlsma MF
Cell Rep Med; 2024 May; 5(5):101523. PubMed ID: 38670098
[TBL] [Abstract][Full Text] [Related]
3. Association between apoptosis inhibitor of macrophage and microsatellite instability status in colorectal cancer.
Huang WJ; Wang X; Zhang ML; Li L; Wang RT
BMC Gastroenterol; 2020 Nov; 20(1):373. PubMed ID: 33172404
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients.
Petrillo A; Salati M; Trapani D; Ghidini M
Curr Drug Targets; 2021; 22(9):1010-1020. PubMed ID: 33155906
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis.
Liu S; Sun X; Xu X; Lin F
J Breast Cancer; 2020 Oct; 23(5):460-483. PubMed ID: 33154823
[TBL] [Abstract][Full Text] [Related]
6. Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors.
McFall T; Schomburg NK; Rossman KL; Stites EC
Cell Commun Signal; 2020 Nov; 18(1):179. PubMed ID: 33153459
[TBL] [Abstract][Full Text] [Related]
7. Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis.
He Y; Wang X
Ann Transl Med; 2020 Sep; 8(17):1050. PubMed ID: 33145269
[TBL] [Abstract][Full Text] [Related]
8. Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry.
Sanz-Garcia E; Brown S; Lavery JA; Weiss J; Fuchs HE; Newcomb A; Postle A; Warner JL; LeNoue-Newton ML; Sweeney SM; Pillai S; Yu C; Nichols C; Mastrogiacomo B; Kundra R; Schultz N; Kehl KL; Riely GJ; Schrag D; Govindarajan A; Panageas KS; Bedard PL
Cancer Res Commun; 2024 Feb; 4(2):475-486. PubMed ID: 38329392
[TBL] [Abstract][Full Text] [Related]
9. Single-cell deconvolution reveals high lineage- and location-dependent heterogeneity in mesenchymal multivisceral stage 4 colorectal cancer.
Berlin C; Mauerer B; Cauchy P; Luenstedt J; Sankowski R; Marx L; Feuerstein R; Schaefer L; Greten FR; Pesic M; Groß O; Prinz M; Ruehl N; Miketiuk L; Jauch D; Laessle C; Jud A; Biesel EA; Neeff H; Fichtner-Feigl S; Holzner PA; Kesselring R
J Clin Invest; 2023 Dec; 134(5):. PubMed ID: 38153787
[TBL] [Abstract][Full Text] [Related]
10. Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer.
Zhong Y; Yang K; Qin X; Luo R; Wang H
Clin Colon Rectal Surg; 2023 Nov; 36(6):415-422. PubMed ID: 37795471
[TBL] [Abstract][Full Text] [Related]
11. Metastasis organotropism in colorectal cancer: advancing toward innovative therapies.
He K; Wang Z; Luo M; Li B; Ding N; Li L; He B; Wang H; Cao J; Huang C; Yang J; Chen HN
J Transl Med; 2023 Sep; 21(1):612. PubMed ID: 37689664
[TBL] [Abstract][Full Text] [Related]
12. The molecular biology of peritoneal metastatic disease.
Bootsma S; Bijlsma MF; Vermeulen L
EMBO Mol Med; 2023 Mar; 15(3):e15914. PubMed ID: 36700339
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal injection of class A TLR9 agonist enhances anti-PD-1 immunotherapy in colorectal peritoneal metastases.
Jiang T; Zhang H; Li Y; Jayakumar P; Liao H; Huang H; Billiar TR; Deng M
JCI Insight; 2022 Oct; 7(20):. PubMed ID: 36278484
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of colorectal cancer related peritoneal metastatic disease.
Lenos KJ; Bach S; Ferreira Moreno L; Ten Hoorn S; Sluiter NR; Bootsma S; Vieira Braga FA; Nijman LE; van den Bosch T; Miedema DM; van Dijk E; Ylstra B; Kulicke R; Davis FP; Stransky N; Smolen GA; Coebergh van den Braak RRJ; IJzermans JNM; Martens JWM; Hallam S; Beggs AD; Kops GJPL; Lansu N; Bastiaenen VP; Klaver CEL; Lecca MC; El Makrini K; Elbers CC; Dings MPG; van Noesel CJM; Kranenburg O; Medema JP; Koster J; Koens L; Punt CJA; Tanis PJ; de Hingh IH; Bijlsma MF; Tuynman JB; Vermeulen L
Nat Commun; 2022 Aug; 13(1):4443. PubMed ID: 35927254
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape of paired primary and synchronous metastatic lymph node in chemotherapy naive gallbladder cancer.
Fan B; Xu X; Wang X
Mol Biol Rep; 2022 Feb; 49(2):1295-1301. PubMed ID: 34988893
[TBL] [Abstract][Full Text] [Related]
16. The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden.
Hallam S; Stockton J; Bryer C; Whalley C; Pestinger V; Youssef H; Beggs AD
Sci Rep; 2020 Nov; 10(1):18900. PubMed ID: 33144643
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone.
Mirnezami R; Mehta AM; Chandrakumaran K; Cecil T; Moran BJ; Carr N; Verwaal VJ; Mohamed F; Mirnezami AH
Br J Cancer; 2014 Oct; 111(8):1500-8. PubMed ID: 25225906
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.
Hallam S; Tyler R; Price M; Beggs A; Youssef H
BJS Open; 2019 Oct; 3(5):585-594. PubMed ID: 31592510
[TBL] [Abstract][Full Text] [Related]
19. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
